EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Tirzepatide reduced alcohol use in three patients with alcohol-associated liver disease, type 2 diabetes, and obesity

Hiroki Takizawa iD, Akiko Tsuda, Hidehisa Suriki, Hideki Amagane

Endocrinology, Diabetes & Metabolism Case Reports · 01.04.2026 · 2026 (2)

DOI: 10.1530/edm-26-0002 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Endocrinology, Diabetes & Metabolism Case Reports, online erschienen am 01.04.2026. Verfasst von Hiroki Takizawa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Kido Hospital, Niigata, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report three obese patients with type 2 diabetes and alcohol-associated liver disease (ALD), including one patient with alcohol use disorder, who exhibited reduced alcohol intake after the initiation of tirzepatide. Although tirzepatide has shown beneficial effects on liver fibrosis in metabolic dysfunction-associated steatohepatitis, its effect on ALD or alcohol intake has not been reported. After the initiation of tirzepatide, all patients demonstrated decreased alcohol consumption, improved liver function, and better metabolic control. These findings suggest that tirzepatide can provide additional benefits for ALD by reducing alcohol intake while improving metabolic risk factors, potentially offering a novel therapeutic option for this high-risk population. Learning points

Schlagwörter

Stichwörter der Autor:innen

alcohol use disorderalcohol-associated liver diseasediabetesobesitytirzepatide

Autor:innen und Institutionen

  • Department of Internal Medicine, Kido Hospital, Niigata, Japan.
  • Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan.
  • Department of Psychiatry, Kohdo Hospital, Niigata, Japan.

ORCID-Profile: Hiroki Takizawa

Zitieren

APA

Takizawa, H., Tsuda, A., Suriki, H., & Amagane, H. (2026). Tirzepatide reduced alcohol use in three patients with alcohol-associated liver disease, type 2 diabetes, and obesity. Endocrinology, Diabetes & Metabolism Case Reports, 2026(2). https://doi.org/10.1530/edm-26-0002

Vancouver

Takizawa H, Tsuda A, Suriki H, Amagane H. Tirzepatide reduced alcohol use in three patients with alcohol-associated liver disease, type 2 diabetes, and obesity. Endocrinology, Diabetes & Metabolism Case Reports. 2026;2026(2). doi:10.1530/edm-26-0002

BibTeX
@article{Takizawa2026,
  author = {Takizawa, Hiroki and Tsuda, Akiko and Suriki, Hidehisa and Amagane, Hideki},
  title = {Tirzepatide reduced alcohol use in three patients with alcohol-associated liver disease, type 2 diabetes, and obesity},
  journal = {Endocrinology, Diabetes & Metabolism Case Reports},
  year = {2026},
  volume = {2026},
  number = {2},
  doi = {10.1530/edm-26-0002}
}
Kostenlos starten →